- Home
- FTHM vs GRML Comparison
FTHM vs GRML Comparison
Compare FTHM & GRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FTHM | GRML |
|---|---|---|
| Founded | 2010 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.8M | 29.2M |
| IPO Year | 2020 | 2022 |
Fundamental Metrics
Financial Performance| Metric | FTHM | GRML |
|---|---|---|
| Price | $0.38 | $9.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 16.7M |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.71 | 31.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $420,477,000.00 | N/A |
| Revenue This Year | $9.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $0.40 | $0.16 |
| 52 Week High | $1.92 | $18.21 |
Technical Indicators
Market Signals| Indicator | FTHM | GRML |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 57.64 |
| Support Level | $0.40 | $0.53 |
| Resistance Level | $0.92 | $11.66 |
| Average True Range (ATR) | 0.04 | 2.25 |
| MACD | -0.01 | 0.21 |
| Stochastic Oscillator | 2.38 | 46.68 |
Price Performance
Historical ComparisonAbout FTHM Fathom Holdings Inc.
Fathom Holdings Inc is a national, technology-driven, real estate services platform integrating residential brokerage, mortgage, title, and Software as a Service (SaaS) offerings to brokerages and agents by leveraging intelliAgent , proprietary cloud-based software. The Company's three operating and reportable segments: Real Estate Brokerage, Mortgage, and Title. The majority of revenue is from Real Estate Brokerage, which provides real estate brokerage services.
About GRML Greenland Mines Ltd. Common Stock
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.